A therapeutic vaccine for AIDS has been developed at the Timoné Hospital in Marseille, France, has been successful in animal studies and will soon be tested in humans on 48 people infected with the virus.
Researcher Isabelle Harvoux told reporters that after 13 years of hard work, they have developed a therapeutic vaccine for AIDS. Havao told reporters that after 13 years of hard work, they have developed a vaccine that has been shown to be effective in animal tests against the AIDS virus. Next they will divide 48 HIV-infected people into groups, each group injected with different doses of the vaccine to determine the most effective dose of this vaccine. The infected patients in the human trial will receive the vaccine three times over the course of a year and will be examined monthly at the Timonium Hospital.
The director of the structural biology laboratory at the Timone Hospital, Evano Lori, said that the vaccine is based on the principle of the vaccine. According to Lori, the principle of the vaccine is to attack TAT, a protein in the AIDS virus that functions in the early replication phase, so that the TAT protein cannot prevent the infected person’s immune system from killing the infected cells. The first phase of the trial will end in a year, and the second phase is expected to involve 80 people infected with HIV.